Stanford SPARK

What Stanford SPARK does

Stanford SPARK is an academic translational research program housed within Stanford University School of Medicine, founded in 2006 by Daria Mochly-Rosen and Kevin Grimes. Its stated function is to bridge the gap between academic biomedical discovery and clinical or commercial application by providing milestone-based seed funding (approximately $25,000-$75,000 per project per year), weekly mentoring from a pool of 100-200+ volunteer industry experts drawn from biotech and pharma, and structured educational programming to Stanford-affiliated faculty, clinicians, postdoctoral scholars, and graduate students. Outputs flow through Stanford's Office of Technology Licensing rather than through SPARK directly; since 2006, 48 SPARK projects have been licensed to outside companies and 32 startups have been formed, with the first FDA-approved drug (Attruby/acoramidis, approved November 2024) emerging from the portfolio.

The program's business model is non-commercial: SPARK does not sell products or services and does not generate revenue in the conventional sense. It is funded by a small set of internal Stanford sources — the Maternal and Child Health Research Institute (MCHRI), Bio-X, Spectrum/NIH CTSA, the Stanford Cancer Institute, and the Dean's Office — together with in-kind support from CDD Vault for drug-discovery informatics infrastructure. Strategic value accrues upstream to Stanford via licensing royalties, equity in startups, and reputational returns, while the program's methodology has been exported through the SPARK Global Network, which by 2026 spans more than 60 academic institutions across 20+ countries on six continents. Recent downstream milestones include Bayer's acquisition of European marketing rights for Attruby (March 2025), Novartis's agreement to acquire Excellergy for up to $2 billion (April 2026), and the $85 million Series A emergence of Stylus Medicine (May 2025).

For a PE/VC/M&A audience, SPARK is best understood as an academic translational platform rather than an investable operating company. Its significance lies in (i) the validated methodology and mentor network that have produced the program's first FDA approval and large strategic-buyer transactions, (ii) the global franchise value of the SPARK brand and training infrastructure, and (iii) the optionality embedded in its pipeline of 32+ startups. The principal limitations are the absence of direct commercial revenue, dependence on a narrow set of internal Stanford funding sources, and the structural separation between SPARK's program activities and the licensing economics that flow through Stanford OTL.

Name

Stanford SPARK

Legal name

SPARK Stanford

Website

https://sparkmed.stanford.edu

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Stanford SPARK is an academic translational research program founded in 2006 within Stanford's School of Medicine that provides milestone-based seed funding, industry-expert mentorship, and education to Stanford researchers to advance biomedical discoveries toward clinical and commercial development.

Ownership category

akta.pro rank

Product category

Academic Translational Research Services

NAICS

Grantmaking and Giving Services (81321), Educational Support Services (611710), Voluntary Health Organizations (813212)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Education Grantmaking Foundations (BPAGAKAK)

Keywords

• Translational research program
• Drug discovery mentoring
• Academic seed funding
• Biomedical technology licensing
• Industry advisor network

Headquarters

HQ city

Stanford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Institutional Funding and Grants: SPARK operates primarily through institutional funding from Stanford University, Stanford Maternal and Child Health Research Institute (MCHRI), Stanford Bio-X, Stanford Spectrum (NIH CTSA), Stanford Cancer Institute, and departmental support. Additional in-kind support is provided by CDD Vault for drug discovery informatics.
2. Technology Licensing Revenue: As projects succeed and get licensed to pharmaceutical companies or startups, Stanford receives licensing revenue. SPARK facilitates these technology transfer arrangements but does not directly generate revenue from product sales.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Stanford SPARK is an academic translational research program that provides Stanford researchers with milestone-based seed funding ($25K-$75K per year for two years), structured mentorship from 200+ volunteer industry experts, and education in drug discovery and development. The program moves early-stage biomedical discoveries from academic laboratories toward clinical application and commercialization through licensing, startup formation, or partnerships with pharmaceutical companies.

Product overview

Stanford SPARK is an academic translational research program—not a conventional product company—comprising multiple interconnected offerings: the core SPARK Program in Translational Research (established 2006) provides mentorship, funding, and education to Stanford researchers; the SPARK Scholars Program offers milestone-based funding ($25K-$75K/year) and hands-on advising for two years; the SPARK Course (CSB 240 A/B) teaches drug discovery and development to graduate students; and the SPARK Manual ('A Practical Guide to Drug Development in Academia') is an educational publication available in multiple languages. Weekly seminars, quarterly advisory reviews, and connections to over 100 industry advisors support the ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• SPARK GLOBAL: A network supporting the adoption of the SPARK translational research model at academic institutions worldwide, with programs in over 60 institutions across 20+ countries.

Products and services

• SPARK Program in Translational Research An academic translational research program that provides mentorship, milestone-based funding, and education to Stanford affiliates (professors, clinicians, postdoctoral scholars, and graduate students) to advance biomedical discoveries into treatments for patients. The program includes weekly coaching by volunteer industry experts and connections to commercial partners.
• SPARK Scholars (SPARKees) Program A mentorship and funding program for Stanford affiliates whose product proposals have been accepted for development, providing hands-on advising, milestone-based funding for two years, and weekly seminars with industry and academic experts.
• SPARK Course (CSB 240 A/B: A Practical Approach to Drug Discovery and Development) A graduate-level project-based course where teams of students develop their own drug discovery proposals over a quarter, covering topics including assay development, compound screening, lead optimization, toxicology testing, regulatory issues, clinical trials, and commercialization.
• SPARK: A Practical Guide to Drug Development in Academia A book published by SPARK co-founders Daria Mochly-Rosen and Kevin Grimes to help academic institutions develop their own SPARK Programs. Available in English, Chinese, Japanese, and Korean.
• SPARK Pilot Grants Milestone-based funding ranging between $25,000 and $75,000 per year for SPARK projects, contingent upon completion of prior term goals, with mandatory participation in weekly seminars and quarterly project updates.
• Industry Advisor Mentoring Over 100 volunteer industry executives and advisors provide project feedback, aid in project selection, mentor specific projects one-on-one, and facilitate introductions to potential partners or company formation.

Quantifiable outcome

• 50% of SPARK projects successfully advanced to clinical and commercial sectors
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

19 partnerships are on record, tiered core.

• Stanford Maternal and Child Health Research Institute (MCHRI)coreStrategic or Co-development PartnerMCHRI has been supporting SPARK projects for over 7 years. Its mission to accelerate Stanford discoveries to improve the health of pregnant women and children complements SPARK's own mission. MCHRI has provided funding for numerous projects in child and maternal health, with 11 projects reaching clinic or commercial sectors.
• Stanford Medicine Dean's OfficecoreStrategic or Co-development PartnerFrom its beginning in 2006, SPARK has been supported by the generosity of the Dean of the Stanford School of Medicine. Dean Lloyd Minor's ongoing financial and institutional support has been vital to the growth and expansion of SPARK.
• Stanford Bio-XcoreStrategic or Co-development PartnerSPARK is grateful for the support of Bio-X, Stanford's interdisciplinary biosciences institute, bringing together biomedical and life science researchers, clinicians, engineers, physicists, and computational scientists.
• Stanford Spectrum (NIH CTSA)coreStrategic or Co-development PartnerSPARK is supported by the NIH Clinical & Translational Science Award (CTSA) through the Stanford Center for Clinical and Translational Research and Education (Spectrum).
• Stanford Cancer InstitutecoreStrategic or Co-development PartnerSPARK thanks the Stanford Cancer Institute for its generous support of SPARK projects advancing cancer research and treatment development.
• NovartiscoreStrategic or Co-development PartnerSPARK startup Excellergy, developing a new class of allergy therapeutics called Effector Cell Response Inhibitors (ECRIs), will be acquired by Novartis in a deal worth up to $2 billion in upfront and milestone payments. Excellergy's lead molecule Exl-111 is in Phase I clinical trials.
• BridgeBio Pharma/Eidos TherapeuticscoreStrategic or Co-development PartnerEidos Therapeutics, founded by SPARK scholar Isabella Graef, merged with BridgeBio to develop Attruby (acoramidis) which received FDA approval in November 2024 for ATTR-CM. Bayer acquired European marketing rights in March 2025.
• ALX OncologycoreStrategic or Co-development PartnerALX Oncology, founded based on technology from SPARK advisor Chris Garcia's research, is a public company (NASDAQ: ALXO) developing Evorpacept for cancer treatment. Received FDA Orphan Drug Designation for gastric cancer.
• Astellas PharmacoreStrategic or Co-development PartnerAstellas acquired rights from Auration Biotech (SPARK startup led by Peter Santa Maria) to develop a therapeutic gel for chronic tympanic membrane perforation.
• CuraSen TherapeuticscoreStrategic or Co-development PartnerCuraSen, founded by SPARK scholar Mehrdad Shamloo, closed a $54.5M Series A financing and presented Phase 1b clinical data demonstrating significant increases in cerebral blood flow in patients with mild cognitive impairment or Parkinson's Disease.
• Balance TherapeuticscoreStrategic or Co-development PartnerBalance Therapeutics, founded based on SPARK research by Craig Garner, raised $21M in Series A and B funding for development of treatments for cognitive function in Down syndrome. Phase 2 clinical trials ongoing in Australia.
• Globavir BiosciencescoreStrategic or Co-development PartnerGlobavir Biosciences licensed a two-drug combination therapy from SPARK (Shirit Einav's research) for treatment of dengue and other viral infections. Company is committed to delivering antiviral therapies to the developing world.
• Eiger BioPharmaceuticals (NASDAQ: EIGR)coreStrategic or Co-development PartnerEiger BioPharmaceuticals, founded by Jeffrey Glenn, licensed SPARK technology and ran Phase IB clinical trials. Company is public (NASDAQ: EIGR) and performing multiple phase II studies worldwide.
• SPARK Global NetworkcoreStrategic or Co-development PartnerA number of academic institutions have successfully developed their own SPARK programs, resulting in a global community of translational scientists. SPARK at Stanford actively supports US and international partners with visits, guest lectures, and more. Over 60 institutions in 20+ countries participate.
• SPARK-BIHcoreStrategic or Co-development PartnerSPARK-BIH in Berlin celebrated its 10th anniversary. It has grown into a key player of the translational ecosystem, providing milestone-based funding, mentorship, education, and a global network. Over 220 participants attended the anniversary celebration.
• UniQuest/University of QueenslandcoreStrategic or Co-development PartnerUniQuest, the commercialization arm of University of Queensland in Australia, joined SPARK GLOBAL Network. Will launch SPARK UniQuest in early 2026 under leadership of Dr. Idalia Ridley.
• SPARK The MidlandscoreStrategic or Co-development PartnerSPARK The Midlands, based at Aston University in England, hosted the SPARK Europe Showcase where 77 projects pitched to investors. First UK branch of SPARK GLOBAL.
• Stylus MedicinecoreStrategic or Co-development PartnerStylus Medicine emerged from stealth in May 2025 with $85M Series A financing to develop in vivo genetic medicines platform. Founded by Stanford professors who received SPARK funding and support. Developing novel therapeutic-grade recombinases with lipid nanoparticle delivery.
• National Institute for Pharmaceutical Research and Development (NIPRD)coreStrategic or Co-development PartnerNIPRD in Nigeria will collaborate with SPARK GLOBAL to host SPARK Translational Research Bootcamp and Conference in Abuja, Nigeria in February 2026, including the launch of SPARK Nigeria program.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Regional players

• BioGenerator (St. Louis): BioGenerator creates and funds bio startups from academic research in the St. Louis region, combining lab space, seed funding, and venture creation services. Comparable academic-to-startup pipeline model but operating in a different geographic ecosystem than SPARK.

Direct peers

• Harvard Blavatnik Biomedical Accelerator: Harvard's Blavatnik Biomedical Accelerator provides funding, industry mentorship, and translational support to Harvard faculty for moving discoveries toward commercialization. Closest direct competitor in mission and structure among top US academic accelerators.
• Vanderbilt Center for Neuroscience Drug Discovery (VCNDD): VCNDD translates academic neuroscience discoveries into clinical drug candidates, combining medicinal chemistry, pharmacology, and industry-style project management. Comparable academic drug discovery translation model with industry advisor involvement.
• UCSF Catalyst Program: UCSF Catalyst provides translational awards and industry mentoring to advance UCSF research toward clinical and commercial applications. Comparable academic-to-commercial bridge program at a peer biomedical research institution.
• Penn Medicine Center for Innovation (PCI): Penn's translational research and commercialization arm provides pilot funding, mentorship, and industry access to Penn faculty. Operates a similar milestone-based funding model with industry advisors to advance discoveries to clinic and market.
• SPARK Berlin / SPARK-BIH: SPARK-BIH at the Berlin Institute of Health is the most established international replica of the Stanford SPARK model, providing milestone-based funding, mentorship, and education to academic researchers. Direct sibling program under SPARK GLOBAL, comparable mission and methodology.

Broad incumbents

• NCATS / NIH Cures Acceleration Network: NIH National Center for Advancing Translational Sciences operates the broader federal translational research mission, funding academic-to-clinical translation across the US. Stanford Spectrum (NIH CTSA) already partners with SPARK, and NCATS represents the macro-scale public-sector version of SPARK's mission.
• Cures Within Reach: Non-profit that funds repurposing of existing drugs for new indications, providing grant funding and partnerships to academic researchers. Comparable grantmaking-and-mentorship model focused on translational outcomes, though not tied to a single university.

Others

• Wellcome Leap: Wellcome Leap funds bold translational research programs with milestone-based structures to accelerate health breakthroughs. Operates at much larger scale and on a foundation model, but shares SPARK's emphasis on milestone-driven translation of academic discoveries.
• Milken Institute FasterCures: Non-profit think tank and convener focused on accelerating medical research translation. Thematically aligned with SPARK's mission but operates through policy, convening, and capital-formation initiatives rather than direct project funding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=WWhVDuwhrVM
• LinkedInlinkedin.com/company/spark-stanford

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stanford SPARK